中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
4期
25-26
,共2页
高剂量%氯吡格雷%冠状动脉%心肌灌注
高劑量%氯吡格雷%冠狀動脈%心肌灌註
고제량%록필격뢰%관상동맥%심기관주
High dose%Clopidogrel%Coronary%Myocardial perfusion
目的 探讨高负荷剂量氯吡格雷对直接经皮冠状动脉介入患者心肌灌注的影响.方法 收集自2009年2月至2014年2月接受经皮冠状动脉介入心肌灌注的病例80例,随机分为对照组40例(术前6h顿服300 mg氯吡格雷)和实验组40例(术前6h顿服600 mg氯吡格雷).结果 对照组心脏损伤血清标记物各项指标:血清肌酸肌酶水平(CK) (96.8±16.2)IU/ml,血清肌酸肌酶同工酶水平(CK-MB) (9.9±2.7)IU/ml,和肌钙蛋白水平T(CTnT)(1.6±0.5)mg/ml.实验组CK (45.7±8.1)IU/mL,CK-MB(6.5±1.6) IU/mL,T (CTnT)(1.0±0.1) mg/ml;对照组凝血功能指标:凝血酶原时间(PT)(11.8±2.2)s,活化部分凝血活酶时间(APTT)(37.6±4.0)s,和血小板计数(PLT)(225.8±23.5)×109/L.实验组PT (13.5±3.4)s,APTT(39.6±3.9)s,PLT(189.3±21.5)×109/L;对照组事件不良事件发生总率为28％,病死率为6％.实验组不良事件发生总率为10％,病死率为2％.结果显示实验组临床效果优于对照组,P ＜0.05,差异有统计学意义.结论 实行冠脉介入术PCI的患者中实验组比对照组更好地抑制了血小板凝集,临床预后有所改善,可考虑临床中广泛推广.
目的 探討高負荷劑量氯吡格雷對直接經皮冠狀動脈介入患者心肌灌註的影響.方法 收集自2009年2月至2014年2月接受經皮冠狀動脈介入心肌灌註的病例80例,隨機分為對照組40例(術前6h頓服300 mg氯吡格雷)和實驗組40例(術前6h頓服600 mg氯吡格雷).結果 對照組心髒損傷血清標記物各項指標:血清肌痠肌酶水平(CK) (96.8±16.2)IU/ml,血清肌痠肌酶同工酶水平(CK-MB) (9.9±2.7)IU/ml,和肌鈣蛋白水平T(CTnT)(1.6±0.5)mg/ml.實驗組CK (45.7±8.1)IU/mL,CK-MB(6.5±1.6) IU/mL,T (CTnT)(1.0±0.1) mg/ml;對照組凝血功能指標:凝血酶原時間(PT)(11.8±2.2)s,活化部分凝血活酶時間(APTT)(37.6±4.0)s,和血小闆計數(PLT)(225.8±23.5)×109/L.實驗組PT (13.5±3.4)s,APTT(39.6±3.9)s,PLT(189.3±21.5)×109/L;對照組事件不良事件髮生總率為28％,病死率為6％.實驗組不良事件髮生總率為10％,病死率為2％.結果顯示實驗組臨床效果優于對照組,P ＜0.05,差異有統計學意義.結論 實行冠脈介入術PCI的患者中實驗組比對照組更好地抑製瞭血小闆凝集,臨床預後有所改善,可攷慮臨床中廣汎推廣.
목적 탐토고부하제량록필격뢰대직접경피관상동맥개입환자심기관주적영향.방법 수집자2009년2월지2014년2월접수경피관상동맥개입심기관주적병례80례,수궤분위대조조40례(술전6h돈복300 mg록필격뢰)화실험조40례(술전6h돈복600 mg록필격뢰).결과 대조조심장손상혈청표기물각항지표:혈청기산기매수평(CK) (96.8±16.2)IU/ml,혈청기산기매동공매수평(CK-MB) (9.9±2.7)IU/ml,화기개단백수평T(CTnT)(1.6±0.5)mg/ml.실험조CK (45.7±8.1)IU/mL,CK-MB(6.5±1.6) IU/mL,T (CTnT)(1.0±0.1) mg/ml;대조조응혈공능지표:응혈매원시간(PT)(11.8±2.2)s,활화부분응혈활매시간(APTT)(37.6±4.0)s,화혈소판계수(PLT)(225.8±23.5)×109/L.실험조PT (13.5±3.4)s,APTT(39.6±3.9)s,PLT(189.3±21.5)×109/L;대조조사건불량사건발생총솔위28％,병사솔위6％.실험조불량사건발생총솔위10％,병사솔위2％.결과현시실험조림상효과우우대조조,P ＜0.05,차이유통계학의의.결론 실행관맥개입술PCI적환자중실험조비대조조경호지억제료혈소판응집,림상예후유소개선,가고필림상중엄범추엄.
Objective To investigate the effects of high loading dose of clopidogrel for myocardial perfusionin on patients with percutaneous coronary intervention.Methods Eighty cases of patients underwent percutaneous coronary intervention myocardial perfusion in our hospital from February 2009 to February 2014 were selected and randomly divided into control group (serving dayton 300 mg clopidogrel six hours before surgery) of 40 cases and the experimental group (serving dayton 600 mg clopidogrel six hours before surgery)of 40 cases.Results Serum markers of heart damage indicators in control group were:serum creatine kinase levels (CK) was (96.8 ± 16.2) IU/ml,serum levels of creatine kinase isoenzyme (CK-MB) was (9.9 ± 2.7) IU/ml,and troponin level T (CTnT) was(1.6 ± 0.5) mg/ml.In experimental group,CK was (45.7 ± 8.1) IU/ml,CK-MB was (6.5 ± 1.6) IU/ml,T (CTnT) was (1.0 ± 0.1) mg/ml.Coagulation parameters in control group:prothrombin time (PT) was (11.8 ± 2.2)s,activated partial thromboplastin live enzymes time (APTT)was(37.6 ± 4.0)s,and platelet count (PLT) was (225.8 ± 23.5) × 109/L.In experimental group,PT was (13.5 ± 3.4) s,APTT was (39.6 ±3.9)s,PLT was(189.3 ±21.5) × 109/L.Adverse events incidence in the control group was 28％ and the fatality rate was 6％.Adverse events incidence in the experimental group was 10％ and the fatality rate was 2％.The results showed that the clinical effect of the experimental group were better than that of the control group,and there was significant difference (P ＜ O.05).Conclusions Implementation of PCI in patients with coronary intervention in the experimental group better inhibits platelet aggregation than the control group,and can improve clinical outcomes,so it can be considered clinically widely.
